Page 8 - Lexaria Bioscience News Today

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utilityKELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"

Gainers CohBar, Inc. (NASDAQ:CWBR) shares jumped 161% to $4.05 after the company and Morphogenesis announced they have entered into a definitive...

Lexarias Hormone Study Shows Significant Enhancement in Oral Estradiol ...

900% and 2,000% improvements in peak bloodstream delivery using DehydraTECHKELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a

Hudbay Minerals (NYSE:HBM – Get Rating) and Lexaria Bioscience (OTCMKTS:LXRP – Get Rating) are both small-cap basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a summary of recent […]

CGMP Manufacturing Complete for Lexarias Upcoming U.S. Phase 1b Hypertension ...

Lexaria Bioscience Announces Closing of $2.0 Million Public Offering

KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of

DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.DehydraTECH-CBD has demonstrated exceptional safety and tolerability and a

KELOWNA, BC / ACCESSWIRE / May 10, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2023